Premium
Acute myeloid leukaemia therapeutic innovation and clinical trials: past, present and future
Author(s) -
Craddock Charles
Publication year - 2020
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.17146
Subject(s) - medicine , clinical trial , myeloid leukaemia , disease , chronic myeloid leukaemia , risk stratification , transplantation , minimal residual disease , intensive care medicine , oncology , stem cell , immunology , leukemia , biology , genetics
Summary Outcomes in acute myeloid leukaemia have improved steadily over the last six decades thanks to advances in disease classification, risk stratification and the advent of new drug and transplant therapies. Over this period the UK has made a major contribution to this international effort, both through its delivery of large prospective randomised trials with integrated genomic and measurable residual disease assessments and its pioneering role in the development of allogeneic stem cell transplantation as a potent anti‐leukaemic therapy.